



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	eptinezumab
Brand name	Vyepi®
Dosage forms	100 mg/1 mL and 300 mg/3 mL solution in a vial for intravenous infusion
Manufacturer	Lundbeck Canada Inc.
Submission type	New Submission
Indication reviewed	For the prevention of migraine in adults who have at least 4 migraine days per month
Canada's Drug and Health Technology Agency (CADTH) Reimbursement Reviews (CRR)	Yes, CRR recommended: to Reimburse with clinical criteria and/or conditions. Visit the CRR website for more details: Reimbursement Review Reports CADTH
Drug Benefit Council (DBC)	The DBC now screens drug submissions under review by CADTH to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened eptinezumab. Since eptinezumab is similar to other drugs that were previously reviewed by DBC for the prevention of migraine, the Ministry may accept the CDEC's recommendation for eptinezumab.
Drug Coverage Decision	Limited Coverage benefit. Access the eptinezumab criteria from: www.gov.bc.ca/pharmacarespecialauthority
Date	April 23, 2024
Reason(s)	Drug coverage decision is consistent with the CDEC recommendation.

	<ul style="list-style-type: none"> • Based on CADTH reviews, eptinezumab reduced the frequency of migraines compared to placebo based on the change from baseline in the number of monthly migraine days (MMD) from weeks 1 to 12. Eptinezumab also reduced migraine symptoms in patients, and the use of eptinezumab was well-tolerated. • Based on the submitted list price, eptinezumab was more costly than other anti-calcitonin gene-related peptide (anti-CGRP) therapies used as a preventative treatment for migraines in adults. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.
Other Information	Vyepi® 300 mg/3 mL vial will be listed when the product supply is available.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada’s Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.

